Bioverativ Inc. (BIVV) Tops Q2 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Bioverativ Reports Second Quarter 2017 Performance
August 2, 2017 4:31 PM EDTSecond quarter 2017 revenues up 37.5% year-over-year Second quarter 2017 GAAP net income up 21.4% year-over-year; Non-GAAP net income up 74.1% year-over-year Completed acquisition of True North Therapeutics Full year 2017 guidance updated; Expected revenue growth of 23% to 25%
WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV) today reported financial results for the second quarter of 2017.
Key financial results include:
... More